Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) ...

Rural survivors were more likely to experience chronic pain than urban survivors, at rates of 43.0% and 33.5%, respectively. After controlling for several factors, the investigators found that rural ...

Identifying women eligible for lung cancer screening through screening mammography programs increases enrollment in lung cancer screening.

The Food and Drug Administration has approved Yartemlea ® (narsoplimab-wuug) for the treatment of adult and pediatric patients aged 2 years and older with hematopoietic stem cell transplant ...